Compare Moderna, Inc. (MRNA) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Standard Lithium Ltd — how do they compare? Moderna, Inc. trades at $64.12 (market cap $24.18B), while Standard Lithium Ltd trades at $2.42 (market cap $604.50M). The key difference: Moderna, Inc. is far larger — about 40× Standard Lithium Ltd's market cap, and Moderna, Inc. is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| MRNA | SLI | |
|---|---|---|
Market Cap | $24.18B | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $81.80 | $5.65 |
52-Week Low | $22.36 | $1.93 |
Enterprise Value | $20.33B | $467.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Standard Lithium (SLI) trades at $2.41, down 4.74% on the day, with technical indicators showing a bullish trend despite recent price weakness. The company maintains strong analyst support with 100% buy ratings from 3 analysts, reflecting optimism about its South West Arkansas lithium project development. Recent earnings show improved performance with two consecutive quarterly beats, though the company remains unprofitable with negative ROE and ROA. Institutional interest is growing, with Amundi increasing its stake by 64.9% in Q1 2026 according to SEC filings.
The investment case centers on SLI's transition to production status with major project de-risking events, including a $225M DOE grant and construction contracts. However, significant execution risks remain as the company burns cash with negative operating cash flow. The path to profitability depends on successful project completion and lithium market conditions, creating both substantial upside potential and meaningful downside risk for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
